Skip to main content

Table 3 Main model analysis: incremental costs, QALYsDW gained and ICERs for the CCC intervention compared to business-as-usual

From: Cancer care coordinators in stage III colon cancer: a cost-utility analysis

  Incremental costs per patient (NZ$) QALYsDW) gained per patient ICER (NZ$ per QALYDW)
Model 1: Averaged over heterogeneity and stochastic variation; input parameter uncertainty only
Mean $ 2,271 0.121 $ 18,881
2.5 % percentile $ 1,225 0.070 $ 13,442
Median $ 2,226 0.119 $ 18,786
97.5 % percentile $ 3,641 0.185 $ 24,610
Model 2: Averaged over stochastic variation; both heterogeneity and input parameter uncertainty included in distribution of outputs
Mean $ 2,239 0.120 $ 23,393
2.5 % percentile $ 992 0.036 $ 6,290
Median $ 1,972 0.113 $ 17,864
97.5 % percentile $ 5,007 0.252 $ 72,041
  1. Dollars are NZ$, for the year 2011. All costs and benefits discounted at 3 % per annum